![](https://endpts.com/wp-content/uploads/2022/06/Ben-Zimmer-Priovant-tile.jpg)
Ben Zimmer, Priovant CEO
Roivant unveils latest spinout as Pfizer entrusts JAK1/TYK2 to Priovant
In November, Pfizer disclosed it’s spun out the Phase II dual JAK1/TYK2 inhibitor to a startup formed in collaboration with an unnamed, experienced partner. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.